TECHWIRE 30
(CIX: WRAL30)  1,122.55  down arrow-5.27  (-0.47 %)  Updated: 11:44 AM EST, Jan 30 2015
(NQ: Apple)  119.03  up arrow+0.13  (0.11 %)  Updated: 11:45 AM EST, Jan 30 2015
(NY: QUINTILES)  60.87  down arrow-0.89  (-1.44 %)  Updated: 11:43 AM EST, Jan 30 2015
(OP: BASF SE)  89.74  down arrow-0.58  (-0.64 %)  Updated: 11:32 AM EST, Jan 30 2015
(NQ: BioCryst)  10.36  down arrow-0.32  (-3 %)  Updated: 11:44 AM EST, Jan 30 2015
(NQ: BioDelivery)  13.23  down arrow-0.4  (-2.93 %)  Updated: 11:44 AM EST, Jan 30 2015
(NQ: CEMP)  27.85  down arrow-0.12  (-0.43 %)  Updated: 11:44 AM EST, Jan 30 2015
(NQ: Cisco Systems)  26.53  down arrow-0.69  (-2.53 %)  Updated: 11:45 AM EST, Jan 30 2015
(NQ: Cree)  35.41  down arrow-0.34  (-0.95 %)  Updated: 11:44 AM EST, Jan 30 2015
(NQ: DARA)  0.83  down arrow-0.02  (-2.8 %)  Updated: 11:32 AM EST, Jan 30 2015
(NY: EMC CORPORATION)  26.26  down arrow-0.14  (-0.54 %)  Updated: 11:45 AM EST, Jan 30 2015
(NQ: Extreme Networks)  2.98  down arrow-0.06  (-1.97 %)  Updated: 11:44 AM EST, Jan 30 2015
(NQ: FB)  77.04  down arrow-0.96  (-1.23 %)  Updated: 11:45 AM EST, Jan 30 2015
(NY: GLAXOSMITHKLINE)  44.19  down arrow-0.97  (-2.15 %)  Updated: 11:44 AM EST, Jan 30 2015
(NQ: GOOG)  531.00  up arrow+20.34  (3.98 %)  Updated: 11:44 AM EST, Jan 30 2015
(NY: IBM)  153.60  down arrow-1.88  (-1.21 %)  Updated: 11:44 AM EST, Jan 30 2015
(NY: LH)  114.87  down arrow-1.25  (-1.08 %)  Updated: 11:44 AM EST, Jan 30 2015
(OP: Lenovo Group)  25.80  down arrow-0.06  (-0.23 %)  Updated: 11:28 AM EST, Jan 30 2015
(NY: MRK)  60.97  down arrow-1.12  (-1.8 %)  Updated: 11:45 AM EST, Jan 30 2015
(NQ: Microsoft Corp)  40.83  down arrow-1.18  (-2.81 %)  Updated: 11:45 AM EST, Jan 30 2015
(NQ: NTAP)  37.75  down arrow-0.31  (-0.81 %)  Updated: 11:45 AM EST, Jan 30 2015
(NY: NOVARTIS AG)  97.85  down arrow-1.31  (-1.32 %)  Updated: 11:44 AM EST, Jan 30 2015
(OP: Novozymes A/S)  45.74  up arrow+0.17  (0.37 %)  Updated: 11:20 AM EST, Jan 30 2015
(NY: PFIZER)  31.43  down arrow-0.4  (-1.26 %)  Updated: 11:45 AM EST, Jan 30 2015
(NQ: Pozen)  7.03  down arrow-0.05  (-0.71 %)  Updated: 11:45 AM EST, Jan 30 2015
(NY: RED HAT)  64.04  down arrow-1.71  (-2.6 %)  Updated: 11:45 AM EST, Jan 30 2015
(NQ: BBRY)  10.17  down arrow-0.08  (-0.78 %)  Updated: 11:45 AM EST, Jan 30 2015
(NQ: Salix)  135.13  down arrow-0.01  (-0.01 %)  Updated: 11:44 AM EST, Jan 30 2015
(NQ: SQI)  14.14  down arrow-0.12  (-0.84 %)  Updated: 11:44 AM EST, Jan 30 2015

Posts tagged “Salix”

January 6

Salix CEO is retiring in wake of inventory woes, stock crash

A slide from a Salix presentation Carolyn Logan, chief executive officer of Salix Pharmaceuticals, is retiring as of Jan. 30 in the wake of an inventory snafu that cost the Raleigh-based company some $3 billion in stock value in just a few hours and likely scuttled a merger worth as much as $10 billion.

Updated December 17, 2014

Premium Lock Will Red Hat deliver earnings surprise? New IBM deal may be boost

Red Hat     Red Hat is set to announce its latest quarterly financials on Thursday, and Wall Street won't be surprised if the Hatters deliver better-than-expected results. Or will the Hatters disappoint? A new IBM deal may give Red Hat a boost going forward.

December 17, 2014

Premium Lock Salix stock rebounds on news of inventory reduction plan

A slide from a Salix presentation Salix Pharmaceuticals shares rebounded 7 percent Tuesday on news that the Raleigh-based company will launch a plan to reduce drug inventory by the end of 2015. Salix was rocked in November when it acknowledged big inventory problems.

Updated November 13, 2014

Premium Lock Comcast pushes Time Warner merger; nContact lands $20M; Salix CFO's severance deal; YouTube adds music subscriptions

Bulldog In today's Bulldog wrapup of technology and life science news: Comcast pushing "full steam" for Time Warner merger; RTP firm raises $20 million; Salix CFO gets severance package; and YouTube launches a subscription music service.

November 7, 2014

Premium Lock Analysts grill Salix exes after CFO, inventory news drive down shares 40%

The chief financial officer at Salix is out; the Raleigh-based drug company reports inventory of a leading product is months higher than previously reported; and Wall Street dumps Salix shares with the price plummeting 40 percent. So when CEO Carolyn Logan opened an earnings conference call with analyst, the knives were out.

A slide from a Salix presentation A slide from a Salix presentation

November 4, 2014

Premium Lock Russia removes Apple statue; Micell finds stent partner; $89B in ecommerce for Christmas; new Salix drug; SciQuet's product update

Bulldog In today's Bulldog wrapup of technology and life science news: Russia removes an Apple statue after Apple CEO comes 'out;' Micell finds partner for stents in Europe; $89 billion forecast for ecommerce sales; Salix launches new drug; and SciQuest updates its product suite.

Updated October 8, 2014

Premium Lock Lenovo class-action suit; new GSK probe; AT&T data breach; Salix drug wins OK; Facebook's anonymous app; Lenovo-NEC deal

Bulldog In today's Bulldog blog wrapping up the latest technology and life science news: Lenovo settles a class-action suit over Wi-Fi; GSK faces another bribery investigation; AT&T data breach; FDA OKs Salix colitis treatment; Facebook is developing an app for anonymous posts; and Lenovo extends its partnership with NEC.

Updated October 3, 2014

Premium Lock Salix calls off $2.7B merger, cites US tax policy; stock surges

Salix     Salix Pharmaceuticals says a tougher U.S. tax policy against merger deals designed to lower taxes by moving companies overseas is why a $2.7 billion merger with Italy's Cosmo Pharmaceuticals is being called off. The deal will cost Salix a $25 million termination fee.

Updated September 24, 2014

Premium Lock $10B deal? Sale talk drives Salix shares to record high

Salix     Raleigh-based Salix Pharmaceuticals is talking a possible deal with Allergan, according to multiple media reports. A deal would be worth $10 billion or more as speculation drives up the price of Salix shares to a record high.

September 23, 2014

Premium Lock Cisco execs sell $19M in shares; Nortel trial nears end; GSK launches 2 startups; Salix $100M settlement; AT&T Amazon bundle

Bulldog In today's wrapup of tech and life science news: Several Cisco executives sell $19 million in shares; Nortel's huge bankruptcy trial nears end; GSK launches two startups; Salix reaches a $100M settlement; and AT&T's new entertainment bundle includes Amazon Prime.

August 20, 2014

Premium Lock Uber hires Obama exec; Salix near deal close; Ballmer leaves Microsoft board; Lenovo's NFL Fantasy; HTC's new phone

Bulldog In today's Bulldog roundup of tech and life science news: Uber hires former Obama exec to help with lobbying; Salix nears deal close; Ballmer quits Microsoft board; Lenovo's new NFL Fantasy contest; HTC's new phone runs Windows.

July 17, 2014

Premium Lock Salix wins FDA approval for drug to treat rare genetic disorder

Salix Raleigh-based Salix Pharmaceuticals has received FDA approval for a drug to treat a rare genetic disorder called hereditary angloedema.

Updated July 10, 2014

Premium Lock Salix stock sags despite merger deal that boosts drug pipeline, lowers tax rate

If investors are fretting, it could be because Salix shareholders will be on the hook for taxes they weren't expecting to pay. The company notes in its securities filings that the conversion of Salix stock into Salix plc stock is considered a taxable event, meaning all Salix shareholders will owe taxes when the deal closes even if they don't sell their shares. Learn more about the deal.

Salix Salix

July 9, 2014

Premium Lock Salix to merge with Ireland unit of Cosmo Pharma in stock deal

Salix Pharmaceuticals (NASDAQ:SLXP) is merging with a subsidiary of Italian drug company Cosmo Pharmaceuticals in a deal that brings Salix new drug products and also reduces the Raleigh company's taxes.

Salix Salix

Updated February 27, 2014

Premium Lock Salix strikes $12M licensing deal for bowel prep drug

Salix     Raleigh-based Salix Pharmaceuticals, which focuses on gastrointestinal treatments, is adding another product to its lineup. Salix is committing $12 million plus royalties to RedHill Biopharma for a bowel prep drug.

February 25, 2014

Premium Lock Salix prevails in $150M suit filed by drug partner

Salix In a legal fight dating to 2011, Raleigh-based Salix Pharmaceuticals has won a jury decision that throws out a lawsuit filed against it by drug partner Napo Pharmaceuticals.

January 30, 2014

Premium Lock FDA accepts new drug filing for Salix rectal inflammation drug

Salix A proposed treatment for a difficult to threat form of rectal inflammation licensed by Salix Pharmaceuticals is moving closer to approval by the FDA.

Updated January 14, 2014

Premium Lock Expanding Salix sales force expected to grow drug sales to $1.6B in 2014

Salix Salix Pharmaceuticals expects it will reach $1.6 billion in total product revenue this year. WRALtechWire Insiders can read more details on the gastrointestinal pharma's projections following the close of its $2.8 billion acquisition of Santarus as its stock hits a new record high.

January 3, 2014

Premium Lock Salix closes on $2.6B deal for San Diego pharma Santarus

Salix, a specialty pharmaceutical company focused on gastrointestinal treatments, said it will acquire all of the outstanding common stock of Santarus at the price of $32 per share, a 37.9 premium over the company's Thursday closing price of $23.20

Salix Salix

Updated November 7, 2013

Premium Lock Salix to acquire San Diego pharma Santarus for $2.6B

Salix, a specialty pharmaceutical company focused on gastrointestinal treatments, said it will acquire all of the outstanding common stock of Santarus at the price of $32 per share, a 37.9 premium over the company's Thursday closing price of $23.20

Salix Salix

Techwire Inside Partners
The Skinny: A Blog by Rick Smith